BUZZ — Leerink sees life — science tools benefiting from Anthropic's push into biology

* Leerink Partners says Anthropic's growing focus on biology could boost demand for laboratory automation, experiments and large-scale data needed to validate AI predictions * Brokerage sees biotech firm Twist Bioscience as the "single most important beneficiary", citing demand for synthetic DNA used to turn AI-designed proteins into testable molecules * Says Anthropic is funding laboratory testing of 5,000 protein designs using Twist's synthetic DNA, highlighting the company's role in AI-driven drug discovery * Leerink says Anthropic's Claude analyzed complex laboratory data in 19-23 minutes, potentially allowing researchers to move more quickly to subsequent experiments * Brokerage says early protein-design results are promising, but more data and lab testing will be needed to develop formats suitable for medicines (Reporting by Kunal Das in Bengaluru) ((mailto:Kunal.Das2@thomsonreuters.com;)